Health Care·Biotechnology·$24.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.96 | N/A | -41.43% |
management commentary, guidance changes, and full analysis available with Pro.
| -41.43% |
Tone: Defensive
Overall, management expressed concerns about recent performance but remains committed to their strategic goals. They highlighted the importance of innovation in their pipeline.
Management acknowledged the challenges faced during the quarter.
They emphasized a focus on long-term growth despite short-term setbacks.
This earnings report indicates that United Therapeutics faced challenges in the fourth quarter, leading to a significant miss on EPS expectations. The stock reacted negatively, dropping 6.25%. Investors may be concerned about the company's ability to meet future earnings expectations without updated guidance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ONEOK INC NEW
Feb 24, 2020